$EVOK
Evoke Pharma Inc

2022 Q4 Form 10-Q Financial Statement

#000095017022023912 Filed on November 09, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $796.4K $832.1K $930.5K
YoY Change 120.86% -10.57%
Cost Of Revenue $190.1K $89.78K $58.44K
YoY Change 39.07% 53.63%
Gross Profit $606.3K $742.3K $872.0K
YoY Change 170.8% -14.87%
Gross Profit Margin 76.13% 89.21% 93.72%
Selling, General & Admin $2.289M $2.614M $2.635M
YoY Change 31.88% -0.78% 40.57%
% of Gross Profit 377.52% 352.2% 302.19%
Research & Development $27.21K $40.39K $81.70K
YoY Change -23.82% -50.56% -61.1%
% of Gross Profit 4.49% 5.44% 9.37%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.316M $2.745M $2.775M
YoY Change 30.76% -1.1% 33.45%
Operating Profit -$1.710M -$1.913M -$1.845M
YoY Change 10.5% 3.67% -11.29%
Interest Expense -$93.44K $126.0K $126.0K
YoY Change -25.25% 0.0% 149.42%
% of Operating Profit
Other Income/Expense, Net $0.00 -$101.3K -$124.6K
YoY Change -18.69% 151.75%
Pretax Income -$1.803M -$2.014M -$1.969M
YoY Change 7.82% 2.25% -7.54%
Income Tax
% Of Pretax Income
Net Earnings -$1.803M -$2.014M -$1.969M
YoY Change 7.82% 2.26% -7.5%
Net Earnings / Revenue -226.43% -242.02% -211.67%
Basic Earnings Per Share -$0.60 -$0.73
Diluted Earnings Per Share -$0.54 -$0.60 -$726.3K
COMMON SHARES
Basic Shares Outstanding 3.343M 3.343M 2.712M
Diluted Shares Outstanding 3.343M 2.712M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.844M $12.35M $11.14M
YoY Change 7.64% 10.84% 77.42%
Cash & Equivalents $9.800M $12.40M $11.10M
Short-Term Investments
Other Short-Term Assets $11.55K $11.55K $11.55K
YoY Change 0.0% 0.0% 0.0%
Inventory $289.4K $220.3K $225.2K
Prepaid Expenses $953.0K
Receivables $624.8K $675.0K $222.2K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $11.72M $13.26M $11.60M
YoY Change 11.0% 14.27% 72.89%
LONG-TERM ASSETS
Property, Plant & Equipment $129.1K $153.7K $49.12K
YoY Change 938.37% 212.85% 22.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change
Total Long-Term Assets $129.1K $153.7K $49.12K
YoY Change 938.57% 212.85% 22.8%
TOTAL ASSETS
Total Short-Term Assets $11.72M $13.26M $11.60M
Total Long-Term Assets $129.1K $153.7K $49.12K
Total Assets $11.85M $13.41M $11.65M
YoY Change 12.09% 15.11% 72.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $934.3K $1.021M $530.5K
YoY Change 6.9% 92.39% -31.1%
Accrued Expenses $720.2K $857.3K $859.9K
YoY Change 35.45% -0.3% 14.65%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.655M $1.878M $1.390M
YoY Change 17.7% 35.06% -79.0%
LONG-TERM LIABILITIES
Long-Term Debt $5.000M $5.000M $5.000M
YoY Change 0.0% 0.0% 150.0%
Other Long-Term Liabilities $1.112M $999.6K $486.3K
YoY Change 81.66% 105.57% 872.54%
Total Long-Term Liabilities $6.112M $6.000M $5.486M
YoY Change 8.91% 9.36% 167.23%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.655M $1.878M $1.390M
Total Long-Term Liabilities $6.112M $6.000M $5.486M
Total Liabilities $7.767M $7.878M $6.877M
YoY Change 10.67% 14.56% -20.72%
SHAREHOLDERS EQUITY
Retained Earnings -$115.6M -$113.8M -$105.8M
YoY Change 7.66% 7.65% 9.45%
Common Stock $119.7M $119.4M $110.5M
YoY Change 7.89% 8.01% 16.72%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.085M $5.533M $4.773M
YoY Change
Total Liabilities & Shareholders Equity $11.85M $13.41M $11.65M
YoY Change 12.09% 15.11% 72.57%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$1.803M -$2.014M -$1.969M
YoY Change 7.82% 2.26% -7.5%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.506M -$1.101M -$5.892M
YoY Change 25.49% -81.32% 225.53%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 313.1K
YoY Change -100.0% 184.65%
NET CHANGE
Cash From Operating Activities -2.506M -1.101M -5.892M
Cash From Investing Activities
Cash From Financing Activities 0.000 0.000 313.1K
Net Change In Cash -2.506M -1.101M -5.579M
YoY Change 25.49% -80.27% 228.18%
FREE CASH FLOW
Cash From Operating Activities -$2.506M -$1.101M -$5.892M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
dei Amendment Flag
AmendmentFlag
false
CY2022Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001403708
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36075
dei Entity Registrant Name
EntityRegistrantName
EVOKE PHARMA, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-8447886
dei Entity Address Address Line1
EntityAddressAddressLine1
420 Stevens Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 370
dei Entity Address City Or Town
EntityAddressCityOrTown
Solana Beach
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92075
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
345-1494
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
EVOK
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3343070
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12350024
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9144710
CY2022Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
674970
CY2021Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
295193
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
923746
CY2022Q3 us-gaap Inventory Net
InventoryNet
220304
CY2021Q4 us-gaap Inventory Net
InventoryNet
185534
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
11551
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
11551
CY2022Q3 us-gaap Assets Current
AssetsCurrent
13256849
CY2021Q4 us-gaap Assets Current
AssetsCurrent
10560734
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
153671
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
12428
CY2022Q3 us-gaap Assets
Assets
13410520
CY2021Q4 us-gaap Assets
Assets
10573162
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1020690
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
874028
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
716993
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
519317
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
140300
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12428
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1877983
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1405773
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
13371
CY2022Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
5000000
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
5000000
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
986268
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
612295
CY2022Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
5999639
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
5612295
CY2022Q3 us-gaap Liabilities
Liabilities
7877622
CY2021Q4 us-gaap Liabilities
Liabilities
7018068
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3343070
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3343070
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2721373
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2721373
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
334
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
272
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
119376486
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
110977835
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-113843922
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-107423013
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
5532898
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
3555094
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13410520
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10573162
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
832100
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
930449
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1712275
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1257505
CY2022Q3 evok Cost Of Goods Sold Expenses
CostOfGoodsSoldExpenses
89775
CY2021Q3 evok Cost Of Goods Sold Expenses
CostOfGoodsSoldExpenses
58435
evok Cost Of Goods Sold Expenses
CostOfGoodsSoldExpenses
180310
evok Cost Of Goods Sold Expenses
CostOfGoodsSoldExpenses
191439
CY2022Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
40388
CY2021Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
81699
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
273582
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
554753
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2614488
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2635161
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7334738
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7115605
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
2744651
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
2775295
us-gaap Operating Expenses
OperatingExpenses
7788630
us-gaap Operating Expenses
OperatingExpenses
7861797
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1912551
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1844846
us-gaap Operating Income Loss
OperatingIncomeLoss
-6076355
us-gaap Operating Income Loss
OperatingIncomeLoss
-6604292
evok Forgiveness Of Paycheck Protection Loan And Accrued Interest
ForgivenessOfPaycheckProtectionLoanAndAccruedInterest
105130
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
24714
CY2021Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1421
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
29419
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
7596
CY2022Q3 us-gaap Interest Expense
InterestExpense
126027
CY2021Q3 us-gaap Interest Expense
InterestExpense
126027
us-gaap Interest Expense
InterestExpense
373973
us-gaap Interest Expense
InterestExpense
374024
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-101313
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-124606
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-344554
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-261298
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-2013864
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-1969452
us-gaap Net Income Loss
NetIncomeLoss
-6420909
us-gaap Net Income Loss
NetIncomeLoss
-6865590
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.60
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.60
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.73
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.73
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.57
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.57
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3343070
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3343070
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2711871
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2711871
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3077145
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3077145
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2669070
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2669070
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
3555094
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
381061
CY2022Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3548
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
171521
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2173665
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
1934011
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
366924
CY2022Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
145445
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7123455
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2233380
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
7191010
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
355752
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-2013864
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
5532898
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-3214623
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
561348
CY2021Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1304846
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13070154
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2605495
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
7811384
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
399411
CY2021Q2 evok Issuance Of Common Stock From Stock Option Exercise Value
IssuanceOfCommonStockFromStockOptionExerciseValue
45454
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-2290643
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
5965606
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
463995
CY2021Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
6421
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
313107
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-1969452
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
4773256
us-gaap Net Income Loss
NetIncomeLoss
-6420909
us-gaap Net Income Loss
NetIncomeLoss
-6865590
evok Forgiveness Of Paycheck Protection Loan And Accrued Interest1
ForgivenessOfPaycheckProtectionLoanAndAccruedInterest1
-105130
us-gaap Share Based Compensation
ShareBasedCompensation
1103737
us-gaap Share Based Compensation
ShareBasedCompensation
1424754
evok Non Cash Lease Expense
NonCashLeaseExpense
12428
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
379777
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
198855
evok Increase Decrease In Prepaid Deferred Expense Inventory And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseInventoryAndOtherAssets
-888976
evok Increase Decrease In Prepaid Deferred Expense Inventory And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseInventoryAndOtherAssets
-1055913
evok Increase Decrease In Accounts Payable And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndOtherCurrentLiabilities
146662
evok Increase Decrease In Accounts Payable And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndOtherCurrentLiabilities
-835632
evok Accrued Compensation
AccruedCompensation
-197676
evok Accrued Compensation
AccruedCompensation
205442
evok Accrued Interest Expense
AccruedInterestExpense
373973
evok Accrued Interest Expense
AccruedInterestExpense
374236
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-12428
evok Milestone Payment
MilestonePayment
-5000000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4089662
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10355746
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
14375000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1304846
evok Proceeds From Issuance Of Common Stock At Market Offering
ProceedsFromIssuanceOfCommonStockAtMarketOffering
7443969
evok Proceeds From Issuance Of Common Stock At Market Offering
ProceedsFromIssuanceOfCommonStockAtMarketOffering
319528
evok Payment Of Common Stock Offering Cost At Market Offering
PaymentOfCommonStockOfferingCostAtMarketOffering
148993
evok Payment Of Common Stock Offering Cost At Market Offering
PaymentOfCommonStockOfferingCostAtMarketOffering
6421
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
45454
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7294976
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13428715
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3205314
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3072969
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9144710
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8068939
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12350024
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11141908
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
153671
us-gaap Loans Assumed1
LoansAssumed1
105130
CY2022Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-12 reverse stock split
evok Entity Incorporation Month And Year Of Incorporation
EntityIncorporationMonthAndYearOfIncorporation
2007-01
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12400000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
1.00
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
569166
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
1.00
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2022Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
evok Bad Debt Expense
BadDebtExpense
0
evok Bad Debt Expense
BadDebtExpense
0
CY2022Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
150000
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
150000
CY2022Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
71000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
35000
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
30000
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
491851
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
569166
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
491851
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2022-10-31
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
39000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
134000
CY2022Q3 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P1Y29D
CY2022Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.10
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
37281
us-gaap Operating Lease Payments
OperatingLeasePayments
99417
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
12427
us-gaap Operating Lease Payments
OperatingLeasePayments
12427
CY2007Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
650000
CY2017Q4 evok Common Stock Shares To Be Issued Value
CommonStockSharesToBeIssuedValue
16000000.0
CY2021 evok Issuance Of Common Stock From Warrant Exercise Shares
IssuanceOfCommonStockFromWarrantExerciseShares
0
CY2021 evok Class Of Warrant Or Right Number Of Securities Expired
ClassOfWarrantOrRightNumberOfSecuritiesExpired
13517
evok Issuance Of Common Stock From Warrant Exercise Shares
IssuanceOfCommonStockFromWarrantExerciseShares
0
evok Class Of Warrant Or Right Number Of Securities Expired
ClassOfWarrantOrRightNumberOfSecuritiesExpired
139972
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
139972
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
34.80
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
355752
CY2021Q3 us-gaap Share Based Compensation
ShareBasedCompensation
463995
us-gaap Share Based Compensation
ShareBasedCompensation
1103737
us-gaap Share Based Compensation
ShareBasedCompensation
1424754
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2200000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y4M2D

Files In Submission

Name View Source Status
evok-20220930_lab.xml Edgar Link unprocessable
0000950170-22-023912-index-headers.html Edgar Link pending
0000950170-22-023912-index.html Edgar Link pending
0000950170-22-023912.txt Edgar Link pending
0000950170-22-023912-xbrl.zip Edgar Link pending
evok-20220930.htm Edgar Link pending
evok-20220930.xsd Edgar Link pending
evok-ex10_1.htm Edgar Link pending
evok-ex31_1.htm Edgar Link pending
evok-ex31_2.htm Edgar Link pending
evok-ex32_1.htm Edgar Link pending
evok-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img214338468_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
evok-20220930_cal.xml Edgar Link unprocessable
evok-20220930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
evok-20220930_htm.xml Edgar Link completed
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
evok-20220930_def.xml Edgar Link unprocessable